Mahshid Moein
Neurology with Special Qualifications in Child Neurology · Dallas, TXNPI 1861686248
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $640 and has fallen 78.2% since, to $140 in 2025.
Across 85 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$246
- UCB, Inc.$179
- Greenwich Biosciences, Inc.$146
- Sunovion Pharmaceuticals Inc.$123
- Tris Pharma Inc$100
- Aquestive Therapeutics, Inc.$94
- plus $558 from 18 others
What the payments were for
- Food & beverage$1,41398%
- Education$332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 14 | $246 |
| UCB, Inc. | 10 | $179 |
| Greenwich Biosciences, Inc. | 8 | $146 |
| Sunovion Pharmaceuticals Inc. | 10 | $123 |
| Tris Pharma Inc | 6 | $100 |
| Aquestive Therapeutics, Inc. | 6 | $94 |
| Ironshore Pharmaceuticals Inc. | 4 | $71 |
| Mallinckrodt Enterprises LLC | 3 | $70 |
| Catalyst Pharmaceuticals, Inc. | 3 | $51 |
| Novartis | 3 | $49 |
| Shire North American Group Inc | 3 | $42 |
| Neurelis, Inc. | 3 | $41 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $33 |
| Corium, LLC | 1 | $31 |
| PTC Therapeutics, Inc. | 1 | $29 |
| Eisai Inc. | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Intrabio Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| SK Life Science, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Aprecia Pharmaceuticals, LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Biomarin Pharmaceutical Inc. | 1 | $12 |
How this compares
$1,446 in reported general payments places this provider in the 55th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Other neurology with special qualifications in child neurology in Dallas
- Roy EltermanDallas$5.9M
- Raphael SchiffmannDallas$88K
- Mauricio Delgado-AyalaDallas$75K
- Kaitlin BatleyDallas$74K
- Daniel GossettDallas$36K
- Zurisadai Gonzalez CastilloDallas$30K
- Steven SparaganaDallas$7K
- Berge MinassianDallas$5K
- Charuta JoshiDallas$4K
- David OwenDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.